🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura

Recruitingn/aAges 18 Years - 99 YearsAllFondazione IRCCS Ca' Granda, Ospedale Maggiore Po…
NCT07513948 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * patients with a confirmed diagnosis of iTTP (i.e., ADAMTS13 activity \<10% with anti-ADAMTS13 antibodies detected); * aged ≥ 18 years; * male and female patients; * treated with daratumumab for iTTP. Exclusion Criteria: * patients unwilling or unable to provide their informed consent; * follow-up \< 6 months after daratumumab administration.
💊

What it tests

  • Not listed
📍

Where

1 site
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy